Semaglutide Shows Promise for Reducing Alcohol Consumption in Clinical Trial
First randomized trial finds weekly semaglutide injections reduced alcohol craving and consumption in adults with alcohol use disorder.
Summary
A groundbreaking clinical trial tested semaglutide, a diabetes/obesity medication, in 48 adults with alcohol use disorder. Over 9 weeks, participants receiving weekly semaglutide injections (0.25-1.0mg) showed significant reductions in alcohol consumption during laboratory testing, decreased drinks per drinking day, and lower weekly alcohol cravings compared to placebo. The GLP-1 receptor agonist also reduced cigarette smoking in current smokers. While promising, this small phase 2 study requires larger trials to confirm effectiveness for alcohol addiction treatment.
Detailed Summary
Alcohol use disorder affects millions but fewer than 10% receive treatment, creating a massive healthcare gap. This phase 2 randomized trial investigated whether semaglutide, a GLP-1 receptor agonist approved for diabetes and obesity, could reduce alcohol consumption in non-treatment-seeking adults with alcohol use disorder.
Researchers enrolled 48 participants (71% female, average age 40) who received either weekly semaglutide injections (escalating from 0.25mg to 1.0mg) or placebo over 9 weeks. The primary outcome measured alcohol consumption in controlled laboratory sessions before and after treatment.
Semaglutide demonstrated medium to large effect sizes in reducing laboratory alcohol consumption, with participants consuming significantly fewer grams of alcohol and achieving lower peak blood alcohol concentrations. Weekly assessments showed semaglutide reduced drinks per drinking day and alcohol craving compared to placebo, though it didn't affect total drinking days or average daily consumption. Notably, smokers in the semaglutide group also reduced cigarette use.
These findings provide the first prospective evidence that low-dose semaglutide can meaningfully reduce alcohol consumption and craving. The results are particularly significant given the limited FDA-approved treatments for alcohol use disorder and the medication's existing clinical availability. However, this small pilot study requires validation in larger, longer-duration trials before clinical implementation.
Key Findings
- Semaglutide reduced laboratory alcohol consumption with medium-to-large effect sizes
- Weekly alcohol craving decreased significantly compared to placebo
- Drinks per drinking day declined, though total drinking days unchanged
- Cigarette smoking also decreased in current smokers receiving semaglutide
- Treatment was well-tolerated with no serious adverse events
Methodology
Double-blind, placebo-controlled trial with 48 participants receiving escalating semaglutide doses (0.25-1.0mg weekly) over 9 weeks. Combined clinical outpatient visits with controlled laboratory alcohol self-administration sessions to objectively measure consumption.
Study Limitations
Small sample size (48 participants) limits generalizability. Short 9-week duration doesn't assess long-term efficacy or safety. Participants were non-treatment-seeking, so results may not apply to those actively seeking alcohol treatment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.